

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Lupin introduces world's first fixed-dose triple combination drug for COPD management

06 October 2026 | News

For the long-term management and treatment of moderate to severe COPD



Mumbai-based pharma major Lupin has launched Formoflo-G® MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI).

The launch marks a significant advancement in respiratory care, expanding treatment options for patients living with COPD.

Lupin Formoflo-G® is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability.

Commenting on the launch, Nilesh Gupta, Managing Director, Lupin, said, "As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G® MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases."

Ranked #2 in the respiratory therapy segment in India (*QVIA, MAT Mar 2026*), Lupin continues to strengthen its leadership in respiratory care with the launch of Formoflo-G® MDI, reinforcing its focus on addressing unmet patient needs through innovation-driven therapies.